Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032 (1)

1
Molecular Oncology Diagnostics Market -
A Global and Regional Analysis
Table of Content
T E K R A M C I T S
O N G A I D Y G O L O C N O R A L U C
E L O M L A B
Focus on Product, Technology, Application,
Cancer Type, End User, and Region Analysis and
Forecast 2022-2032 November 2022
O L 1 G All rights reserved at BIS Research Inc.
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
Copyright 2022 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting, or otherwise reproducing
any or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered whether for sale or
otherwise to any third party.
2
3

• Table of Content
• Executive Summary.................................
  .........................................24
• 1. Market ........................................
  ...............................................32
• 1.1 Product Definition............................
  ..................................................
  ..............33
• 1.2 Inclusion and Exclusion.......................
  ..................................................
  .........34
• 1.3 Scope of the Study ...........................
  ..................................................
  .............34
• 1.4 Key Questions Answered in the
  Report............................................
  .............35
• 2. Research Methodology ..........................
  ....................................37
• 2.1 Global Molecular Oncology Diagnostics Market
  Research Methodology ............................
  ..................................................
  ......................37
• 2.2 Primary Data Sources .........................
  ..................................................
  ..........37
• 2.3 Secondary Data Sources .......................
  ..................................................
  .......38
• 2.4 Market Estimation Model.......................
  ..................................................
  ........39
• 2.5 Criteria for Company Profiling................
  ..................................................
  ......41
• 3. Global Molecular Oncology Diagnostics Market
  Overview .........42
• 3.1 Market Overview ..............................
  ..................................................
  ..............42
• 3.1.1 Evolution of Molecular Cancer Diagnostics
  and Current Status..................... 42
• Global Molecular Oncology Diagnostics Market Size
  and Forecast (2021-2032) ........................
  ..................................................
  .............................43
• Global Incidence and Prevalence of Cancer (by
  Type) ................................44
• 3.3.1 North America .............................
  ..................................................
  ....................... 44

GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
4

• 3.4.1 Impact on Market Size ......................
  ..................................................
  ................. 50
• Liquid Biopsy-Based Cancer Molecular Diagnostics
  ...................................51
• Laboratory Developed Test (LDT) Vs. In Vitro
  Diagnostic (IVD) ..................52
• Role of Companion Diagnostics in the Molecular Onc
  ology Diagnostics Market ........................
  ..................................................
  ................52
• 4. Global Molecular Oncology Diagnostics Market I
  ndustry Analysis.................................
  ..................................................
  ..55
• 4.1 Legal Requirements and Framework in the
  U.S............................................56
• 4.1.1 FDA Regulation ............................
  ..................................................
  ...................... 56
• 4.1.2 CMS Regulation (Reimbursement Scenario)
  ..................................................
  ... 57
• 4.2 Legal Requirements and Framework in
  Europe............................................
  58
• 4.3 Legal Requirements and Framework in
  Asia-Pacific....................................59
  4.3.1 China ....................................
  ..................................................
  ............................... 59 4.3.2
  Japan.............................................
  ..................................................
  ...................... 60
• 5. Market Dynamics ...............................
  ........................................62
• 5.1 Overview..................................
  ..................................................
  .......................63
• 5.1 Impact Analysis .........................
  ..................................................
  ....................63
• 5.2 Growth Drivers...........................
  ..................................................
  ....................65
• 5.2.1 Rising Incidence of Cancer Cases
  ..................................................
  ................... 65
• Launch of Innovative Products in Molecular
  Oncology Diagnostics Ecosystem
  ..................................................
  ..................................................
  ........ 67
• Growth in Biomarker identification and
  Transformations in Molecular Techniques
  ..................................................
  ..................................................
  ....... 67
• 5.3 Growth Restraints.............................
  ..................................................
  .............69
• 5.3.1 Lack of Qualified Professionals.............
  ..................................................
  ........... 69

GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
5

• 5.4.2 Upsurge of Next-Generation Ultrasensitive
  Molecular Diagnostics................ 72
• 6. Competitive Landscape .........................
  ....................................74
• 6.1 Mergers and Acquisitions .....................
  ..................................................
  ........76
• 6.2 Synergistic Activities .......................
  ..................................................
  .............77
• 6.3 Product Launch and Approval
  Activities........................................
  ...............78
• 6.4 Expansion, Insurance, and Other Key
  Developments ..................................79
• 6.5 Market-Share Analysis ........................
  ..................................................
  ..........79
• 6.6 Growth-Share Analysis ........................
  ..................................................
  .........81
• Global Molecular Oncology Diagnostics Market (by
  Product),
• Million, 2021-2032 ..............................
  ......................................83
• 7.1 Overview......................................
  ..................................................
  ...................84
• 7.2 Kits and Assays ..............................
  ..................................................
  ...............85
• 7.3 Instruments ..................................
  ..................................................
  ..................87
• 7.4 Software .....................................
  ..................................................
  ....................88
• Global Molecular Oncology Diagnostics Market (by
  Technology), Million, 2021-2032..................
  .............................90
• 8.1 Overview......................................
  ..................................................
  ...................91
• 8.2 Polymerase Chain Reaction (PCR)...............
  ..................................................
  93
• 8.3 Next-Generation Sequencing (NGS)
  ..................................................
  ............94
• 8.4 Immunohistochemistry (IHC)....................
  ..................................................
  ....95

GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
6
10.1.1 Solid Tumor ..............................
..................................................
........................ 105 10.1.1.1 Breast
Cancer ...........................................
..................................................
.. 106 10.1.1.2 Lung Cancer .....................
..................................................
.......................... 107 10.1.1.3 Colorectal
Cancer .........................................
................................................
108 10.1.1.4 Prostate Cancer ....................
..................................................
...................... 109 10.1.1.5 Ovarian
Cancer............................................
.................................................
110 10.1.1.6 Other Solid Tumors...................
..................................................
.................. 111 10.1.2 Hematological
Malignancy .......................................
.........................................
112 10.1.2.1 Lymphoma ............................
..................................................
...................... 113 10.1.2.2 Leukemia
..................................................
..................................................
.. 114 10.1.2.3 Multiple Myeloma
..................................................
........................................
115 10.1.2.4 Other Hematological Malignancies
..................................................
............. 116 11. Global Molecular Oncology
Diagnostics Market (by End User), Million,
2021-2032 ........................................
.......................... 118 11.1 Overview......
..................................................
.................................................1
19 11.2 Hospitals and Diagnostic
Centers...........................................
.....................120 11.3 Reference
Laboratories......................................
...........................................121 11.
4 Pharmaceutical and Biotechnology
Companies.........................................
122 11.5 Academic and Research Institutes
...................... Error! Bookmark not
defined. 12. Region .............................
..................................................
...... 124 12.1 Overview.........................
..................................................
..............................125 12.2 North
America ..........................................
..................................................
....127 12.2.1 U.S. .............................
..................................................
.......................................
131 12.2.2 Canada ...............................
..................................................
............................... 134 12.3 Europe
..................................................
..................................................
........138 12.3.1 Germany........................
..................................................
....................................
141 12.3.2 France ...............................
..................................................
................................ 145 12.3.3 U.K.
..................................................
..................................................
.................. 149 12.3.4 Italy
..................................................
..................................................
.................. 152 12.3.5 Spain
..................................................
..................................................
............... 155 6
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
7
12.3.6 Rest-of-Europe ...........................
..................................................
...................... 159 12.4 Asia-Pacific
..................................................
..................................................
162 12.4.1 China ................................
..................................................
.................................
165 12.4.2 India..................................
..................................................
.................................
169 12.4.3 Japan..................................
..................................................
............................... 172 12.4.4 South
Korea.............................................
..................................................
......... 176 12.4.5 Australia....................
..................................................
........................................
179 12.4.6 Rest-of-Asia-Pacific
..................................................
.........................................
183 12.5 Rest-of-the-World (RoW)
..................................................
.............................187 13. Company
Profiles..........................................
........................... 189 13.1 Agilent
Technologies, Inc. ...............................
.............................................191 1
3.1.1 Company Overview............................
..................................................
.............. 191 13.1.2 Role of Agilent
Technologies, Inc. in the Global Molecular
Oncology Diagnostics Market ....................
..................................................
...................... 191 13.1.3 Key Competitors
of the Company ...................................
.................................
191 13.1.4 Business Strategies....................
..................................................
..................... 192 13.1.4.1 Merger and
Acquisition ......................................
...........................................
192 13.1.4.2 Product Launch/Approval
..................................................
........................... 192 13.1.4.3 Expansion
.................................................
..................................................
.. 192 13.1.5 Financials..........................
..................................................
................................
193 13.1.6 Analyst Perspective
..................................................
.........................................
195 13.2 Abbott. .................................
..................................................
.........................196 13.2.1 Company
Overview..........................................
..................................................
196 13.2.2 Role of Abbott. in the Global
Molecular Oncology Diagnostics Market ....... 196
13.2.3 Key Competitors of the Company
..................................................
.................. 196 13.2.4 Key Customers of
the Company.......................................
................................
197 13.2.5 Financials.............................
..................................................
............................. 197 13.2.6 Key
Insights about the Financial Health of the
Company .............................. 199
13.2.7 Analyst Perspective ......................
..................................................
................... 200 13.3 Biocartis NV
..................................................
.................................................2
01
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
8
13.3.1 Company Overview...........................
..................................................
............... 201 13.3.2 Role of Biocartis NV
in the Global Molecular Oncology Diagnostics
Market............................................
..................................................
.................... 201 13.3.3 Key Competitors
of the Company ...................................
.................................
201 13.3.4 Corporate Strategies..................
..................................................
...................... 201 13.3.4.1 Synergistic
Activities .......................................
..............................................
201 13.3.5 Business Strategies....................
..................................................
..................... 202 13.3.5.1 Product
Launch/Approval ..................................
...........................................
202 13.3.6 Financials.............................
..................................................
............................. 203 13.3.7 Analyst
Perspective .....................................
..................................................
.... 203 13.4 Bio-Rad Laboratories, Inc.
..................................................
..........................204 13.4.1 Company
Overview..........................................
..................................................
204 13.4.2 Role of Bio-Rad Laboratories, Inc. in
the Global Molecular Oncology Diagnostics
Market ...........................................
.................................................
204 13.4.3 Key Competitors of the Company
..................................................
.................. 204 13.4.4 Corporate
Strategies........................................
..................................................
205 13.4.4.1 Synergistic Activities
..................................................
...................................
205 13.4.5 Business Strategies....................
..................................................
..................... 205 13.4.5.1 Merger and
Acquisition ......................................
...........................................
205 13.4.5.2 Product Launch/Approval
..................................................
........................... 205 13.4.6 Financials.
..................................................
..................................................
....... 206 13.4.7 Analyst Perspective
..................................................
.........................................
208 13.5 F. Hoffmann-La Roche Ltd.
..................................................
.........................209 13.5.1 Company
Overview..........................................
..................................................
209 13.5.2 Role of F. Hoffmann-La Roche Ltd. in
the Global Molecular Oncology Diagnostics
Market ...........................................
.................................................
209 13.5.3 Key Competitors of the Company
..................................................
.................. 209 13.5.4 Corporate
Strategies........................................
..................................................
210 13.5.4.1 Synergistic Activities
..................................................
...................................
210 13.5.5 Business Strategies....................
..................................................
..................... 210
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
9
13.5.5.1 Product Launch/Approval
..................................................
........................... 210 13.5.5.2 Expansion
.................................................
..................................................
.. 210 13.5.6 Financials..........................
..................................................
................................
211 13.5.7 Analyst Perspective
..................................................
.........................................
214 13.6 QIAGEN N.V...............................
..................................................
...................215 13.6.1 Company
Overview..........................................
..................................................
215 13.6.2 Role of QIAGEN N.V. in the Global
Molecular Oncology Diagnostics
Market............................................
..................................................
.................... 215 13.6.3 Key Competitors
of the Company ...................................
................................. 215 13.6.4 Key
Customers of the Company..........................
.............................................
216 13.6.5 Corporate Strategies..................
..................................................
...................... 216 13.6.5.1 Synergistic
Activities .......................................
..............................................
216 13.6.6 Business Strategies....................
..................................................
..................... 217 13.6.6.1 Merger and
Acquisition ......................................
...........................................
217 13.6.6.2 Product Launch/Approval
..................................................
........................... 217 13.6.7 Financials.
..................................................
..................................................
....... 217 13.6.8 Analyst Perspective
..................................................
.........................................
220 13.7 Thermo Fisher Scientific,
Inc...............................................
.........................221 13.7.1 Company
Overview..........................................
..................................................
221 13.7.2 Role of Thermo Fisher Scientific,
Inc. in the Global Molecular Oncology
Diagnostics Market ..............................
..................................................
............ 221 13.7.3 Key Competitors of the
Company ..........................................
.......................... 221 13.7.4 Corporate
Strategies........................................
..................................................
222 13.7.4.1 Synergistic Activities
..................................................
...................................
222 13.7.5 Business Strategies....................
..................................................
..................... 222 13.7.5.1 Product
Launch/Approval ..................................
...........................................
222 13.7.5.2 Expansion ...........................
..................................................
........................ 222 13.7.6 Financials....
..................................................
..................................................
.... 223 13.7.7 Analyst Perspective
..................................................
.........................................
226 13.8 Danaher. ................................
..................................................
.......................227
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
10
13.8.1 Company Overview...........................
..................................................
............... 227 13.8.2 Role of Danaher. in
the Global Molecular Oncology Diagnostics
Market..... 227 13.8.3 Key Competitors of the
Company ..........................................
.......................... 228 13.8.4 Corporate
Strategies........................................
..................................................
228 13.8.4.1 Synergistic Activities
..................................................
...................................
228 13.8.5 Financials.............................
..................................................
............................. 229 13.8.6 Key
Insights about the Financial Health of the
Company .............................. 231
13.8.7 Analyst Perspective ......................
..................................................
................... 231 13.9 Guardant
Health............................................
.................................................2
32 13.9.1 Company Overview......................
..................................................
.................... 232 13.9.2 Role of Guardant
Health in the Global Molecular Oncology
Diagnostics Market...............................
..................................................
................................. 232 13.9.3 Key
Competitors of the Company .......................
.............................................
232 13.9.4 Key Customers of the
Company...........................................
............................ 233 13.9.5 Corporate
Strategies.......................................
..................................................
. 233 13.9.5.1 Synergistic Activities
..................................................
...................................
233 13.9.6 Business Strategies....................
..................................................
..................... 233 13.9.6.1 Product
Launch/Approval ..................................
...........................................
233 13.9.7 Financials.............................
..................................................
............................. 234 13.9.8 Key
Insights about the Financial Health of the
Company .............................. 236
13.9.9 Analyst Perspective .......................
..................................................
.................. 236 13.10 HTG Molecular
Diagnostics, Inc. ................................
..................................238 13.10.1
Company Overview..................................
..................................................
........ 238 13.10.2 Role of HTG Molecular
Diagnostics, Inc. in the Global Molecular
Oncology Diagnostics Market.......................
..................................................
.. 238 13.10.3 Key Competitors of the Company
..................................................
.................. 238 13.10.4 Business
Strategies........................................
..................................................
. 239 13.10.4.1 Product Launch/Approval
..................................................
........................... 239 13.10.5
Financials........................................
..................................................
.................. 240 13.10.6 Key Insights
about the Financial Health of the Company
.............................. 241
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
11
13.10.7 Analyst Perspective ....................
..................................................
..................... 242 13.11 Illumina, Inc.
..................................................
.................................................2
43 13.11.1 Company Overview......................
..................................................
.................... 243 13.11.2 Role of
Illumina, Inc. in the Global Molecular Oncology
Diagnostics Market...............................
..................................................
................................. 243 13.11.3
Key Competitors of the Company ...................
.................................................
243 13.11.4 Corporate Strategies................
..................................................
........................ 244 13.11.4.1
Synergistic Activities ...........................
..................................................
........ 244 13.11.5 Business Strategies.........
..................................................
................................ 244 13.11.5.1
Merger and Acquisition ...........................
..................................................
.... 244 13.11.6 Financials....................
..................................................
......................................
245 13.11.7 Key Insights about the Financial
Health of the Company ............................
.. 247 13.11.8 Analyst Perspective
..................................................
......................................... 247
13.12 Invivoscribe, Inc...........................
..................................................
................249 13.12.1 Company
Overview..........................................
..................................................
249 13.12.2 Role of Invivoscribe, Inc. in the
Global Molecular Oncology Diagnostics
Market............................................
..................................................
.................... 249 13.12.3 Key
Competitors of the Company .......................
.............................................
249 13.12.4 Corporate Strategies................
..................................................
........................ 249 13.12.4.1
Synergistic Activities ...........................
..................................................
........ 249 13.12.5 Business Strategies.........
..................................................
................................ 250 13.12.5.1
Product Launch/Approval ..........................
..................................................
. 250 13.12.6 Analyst Perspective
..................................................
.........................................
250 13.13 Myriad Genetics, Inc.
..................................................
...................................252 13.13.1
Company Overview..................................
..................................................
........ 252 13.13.2 Role of Myriad Genetics,
Inc. in the Global Molecular Oncology
Diagnostics Market ..............................
..................................................
............ 252 13.13.3 Key Competitors of the
Company ..........................................
.......................... 252 13.13.4
Corporate Strategies..............................
..................................................
.......... 252 13.13.4.1 Synergistic
Activities .......................................
.............................................. 252
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
12
13.13.5 Business Strategies......................
..................................................
................... 253 13.13.5.1 Product
Launch/Approval ..................................
...........................................
253 13.13.6 Financials.........................
..................................................
................................. 254 13.13.7 Key
Insights about the Financial Health of the
Company .............................. 255
13.13.8 Analyst Perspective ......................
..................................................
................... 256 13.14 Sysmex
Corporation.......................................
...............................................257
13.14.1 Company Overview........................
..................................................
.................. 257 13.14.2 Role of Sysmex
Corporation in the Global Molecular Oncology
Diagnostics Market ..............................
..................................................
............ 257 13.14.3 Key Competitors of the
Company ..........................................
.......................... 257 13.14.4
Corporate Strategies..............................
..................................................
.......... 257 13.14.4.1 Synergistic
Activities .......................................
..............................................
257 13.14.5 Business Strategies..................
..................................................
....................... 258 13.14.5.1 Product
Launch/Approval ..................................
...........................................
258 13.14.5.2 Expansion .......................
..................................................
............................ 258 13.14.6
Financials........................................
..................................................
.................. 259 13.14.7 Key Insights about
the Financial Health of the Company
.............................. 260 13.14.8
Analyst Perspective ..............................
..................................................
........... 260
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
13
List of Figures
Figure 1 Annual NIH Funding in Human Genomics Research, Billion, FY2013-FY2019
Figure 2 Global Molecular Oncology Diagnostics Market, Million, 2021-2032
Figure 3 Global Molecular Oncology Diagnostics Market, Dynamics
Figure 4 Share of Key Market Strategies and Developments, January 2019-October 2022
Figure 5 Global Molecular Oncology Diagnostics Market (by Product), Million, 2021 Vs. 2032
Figure 6 Global Molecular Oncology Diagnostics Market (by Technology), Million, 2021 Vs. 2032
Figure 7 Global Molecular Oncology Diagnostics Market (by Application), Million, 2021 Vs. 2032
Figure 8 Global Molecular Oncology Diagnostics Market (by Cancer Type), Million, 2021 Vs. 2032
Figure 9 Global Molecular Oncology Diagnostics Market (by End User), Million, 2021 Vs. 2032
Figure 10 Global Molecular Diagnostics Market (by Region), Million, 2021 Vs. 2032
Figure 11 Role of Diagnostics in Healthcare
Figure 12 Global Molecular Oncology Diagnostics Market Segments
Figure 13 Global Molecular Oncology Diagnostics Market Methodology
Figure 14 Primary Research Methodology
Figure 15 Bottom-Up Approach (Segment-Wise Analysis)
Figure 16 Top-Down Approach (Segment-Wise Analysis)
Figure 17 Global Molecular Oncology Diagnostics Market, Million, 2021-2032
Figure 18 Solid Tumor Prevalence and Incidence Data in Europe, 2020
Figure 19 Hematological Malignancy Prevalence and Incidence Data in North America, 2020
Figure 20 Solid Tumor Prevalence and Incidence Data in Europe, 2020
Figure 21 Hematological Malignancy Prevalence and Incidence Data in Europe, 2020
Figure 22 Solid Tumor Prevalence and Incidence Data in Asia-Pacific, 2020
Figure 23 Hematological Malignancy Prevalence and Incidence Data in Asia-Pacific, 2020
Figure 24 Global Molecular Oncology Diagnostics Market, Million, 2019-2021
Figure 25 Prominent FDA-Approved CDx Tests for Molecular Oncology Diagnostics
Figure 26 FDA Guidelines for CDx Approval
Figure 27 Criteria for CMS Coverage/Reimbursement
Figure 28 Europe In Vitro Diagnostic Devices Regulation Regulatory Process
Figure 29 Workflow for Medical Device Regulations
Figure 30 Global Molecular Diagnostics Market Market Dynamics
Figure 31 Likert Scale
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
13
14
Impact Analysis of Market Drivers and Challenges
on the Global Molecular Oncology Diagnostics
Market
Figure 32
Figure 33
Global Distribution of Cases and Deaths (by
Cancer Type), 2020
Figure 34
Global Incidence for Cancer Types (2017-2019)
Figure 35
Product Upgradations and Technological
Advancements, 2019-2022
Figure 36
Synergistic Activities, 2019-2021
Figure 37
Share of Key Developments and Strategies, January
2019-October 2022
Figure 38
Share of Mergers and Acquisitions (by Company),
January 2019-October 2022
Figure 39
Share of Synergistic Activities (by Company),
January 2019-October 2022
Figure 40
Share of Product Launch and Approval Activities
(by Company), January 2019-October 2022
Share of Expansion, Insurance, and Other Key
Developments (by Company), January 2019- October
2022
Figure 41
Figure 42
Market-Share Analysis for the Global Molecular
Oncology Diagnostics Market, Million, 2021
Growth-Share Analysis of Global Molecular
Oncology Diagnostics Market (by Technology),
2021-2032
Figure 43
Figure 44
Global Molecular Oncology Diagnostics Market (by
Product)
Figure 45
Share of Global Molecular Oncology Diagnostics
Market (by Product), Million, 2021 and 2032
Figure 46
Global Molecular Oncology Diagnostics Market
(Kits and Assays), Million, 2021-2032
Figure 47
Global Molecular Oncology Diagnostics Market
(Instruments), Million, 2021-2032
Figure 48
Global Molecular Oncology Diagnostics Market
(Software), Million, 2021-2032
Figure 49
Global Molecular Oncology Diagnostics Market (by
Technology)
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
Share of Global Molecular Oncology Diagnostics
Market (by Technology), Million, 2021 and 2032
Figure 50
Global Molecular Oncology Diagnostics Market
(Polymerase Chain Reaction), Million, 2021- 2032
Figure 51
Global Molecular Oncology Diagnostics Market
(Next-Generation Sequencing), Million, 2021-
2032
Figure 52
Figure 53
Global Molecular Oncology Diagnostics Market
(Immunohistochemistry), Million, 2021-2032
Global Molecular Oncology Diagnostics Market
(Fluorescence In-Situ Hybridization), Million,
2021-2032
Figure 54
Figure 55
Global Molecular Oncology Diagnostics Market
(Flow Cytometry), Million, 2021-2032
Figure 56
Global Molecular Oncology Diagnostics Market
(Other Technologies), Million, 2021-2032
Share of Global Molecular Oncology Diagnostics
Market (by Application), Million, 2021 and 2032
Figure 57
14
15
Figure 58
Global Molecular Oncology Diagnostics Market
(Clinical Diagnostic), Million, 2021-2032
Figure 59
Global Molecular Oncology Diagnostics Market
(Research Use), Million, 2021-2032
Figure 60
Global Molecular Oncology Diagnostics Market (by
Cancer Type)
Share of Global Molecular Oncology Diagnostics
Market (by Cancer Type), Million, 2021 and 2032
Figure 61
Figure 62
Global Molecular Oncology Diagnostics Market (by
Solid Tumor), Million, 2021 and 2032
Figure 63
Global Molecular Oncology Diagnostics Market
(Breast Cancer), Million, 2021-2032
Figure 64
Global Molecular Oncology Diagnostics Market
(Lung Cancer), Million, 2021-2032
Figure 65
Global Molecular Oncology Diagnostics Market
(Colorectal Cancer), Million, 2021-2032
Figure 66
Global Molecular Oncology Diagnostics Market
(Prostate Cancer), Million, 2021-2032
Figure 67
Global Molecular Oncology Diagnostics Market
(Ovarian Cancer), Million, 2021-2032
Figure 68
Global Molecular Oncology Diagnostics Market
(Other Solid Tumors), Million, 2021-2032
Global Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021 and
2032
Figure 69
Figure 70
Global Molecular Oncology Diagnostics Market
(Lymphoma), Million, 2021-2032
Figure 71
Global Molecular Oncology Diagnostics Market
(Leukemia), Million, 2021-2032
Figure 72
Global Molecular Oncology Diagnostics Market
(Multiple Myeloma), Million, 2021-2032
Global Molecular Oncology Diagnostics Market
(Other Hematological Malignancies), Million,
2021-2032
Figure 73
Share of Global Molecular Oncology Diagnostics
Market (by End User), Million, 2021 and 2032
Figure 74
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
Global Molecular Oncology Diagnostics Market
(Hospitals and Diagnostic Centers), Million,
2021-2032
Figure 75
Figure 76
Global Molecular Oncology Diagnostics Market
(Reference Laboratories), Million, 2021-2032
Global Molecular Oncology Diagnostics Market
(Pharmaceutical and Biotechnology Companies),
Million, 2021-2032
Figure 77
Global Molecular Oncology Diagnostics Market
(Academic and Research Institutes), Million,
2021-2032
Figure 78
Figure 79
Global Molecular Oncology Diagnostics Market
Snapshot (by Region), Million, 2021-2032
Figure 80
Global Molecular Oncology Diagnostics Market (by
Region), Million, 2021-2032
Figure 81
North America Molecular Oncology Diagnostics
Market, Million, 2021-2032
Figure 82
North America Market Dynamics
Figure 83
North America Molecular Oncology Diagnostics
Market (by Country), Million, 2021 and 2032
Figure 84
U.S. Molecular Oncology Diagnostics Market,
Million, 2021-2032
16
Figure 85
U.S. Molecular Oncology Diagnostics Market (by
Cancer Type), Million, 2021-2032
Figure 86
U.S. Molecular Oncology Diagnostics Market (by
Solid Tumor), Million, 2021-2032
U.S. Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021- 2032
Figure 87
Figure 88
Canada Molecular Oncology Diagnostics Market,
Million, 2021-2032
Figure 89
Canada Molecular Oncology Diagnostics Market (by
Cancer Type), Million, 2021-2032
Figure 90
Canada Molecular Oncology Diagnostics Market (by
Solid Tumor), Million, 2021-2032
Canada Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021-2032
Figure 91
Figure 92
Europe Molecular Oncology Diagnostics Market,
Million, 2021-2032
Figure 93
Europe Market Dynamics
Figure 94
Europe Molecular Oncology Diagnostics Market (by
Country), Million, 2021 and 2032
Figure 95
Germany Molecular Oncology Diagnostics Market,
Million, 2021-2032
Figure 96
Germany Molecular Oncology Diagnostics Market (by
Cancer Type), Million, 2021-2032
Figure 97
Germany Molecular Oncology Diagnostics Market (by
Solid Tumor), Million, 2021-2032
Germany Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021-2032
Figure 98
Figure 99 France Molecular Oncology Diagnostics
Market, Million, 2021-2032 Figure 100 France
Molecular Oncology Diagnostics Market (by Cancer
Type), Million, 2021-2032 Figure 101 France
Molecular Oncology Diagnostics Market (by Solid
Tumor), Million, 2021-2032 Figure 102 France
Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021-
2032 Figure 103 U.K. Molecular Oncology
Diagnostics Market, Million, 2021-2032 Figure
104 U.K. Molecular Oncology Diagnostics Market
(by Cancer Type), Million, 2021-2032 Figure
105 U.K. Molecular Oncology Diagnostics Market
(by Solid Tumor), Million, 2021-2032 Figure 106
U.K. Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021-
2032 Figure 107 Italy Molecular Oncology
Diagnostics Market, Million, 2021-2032 Figure
108 Italy Molecular Oncology Diagnostics Market
(by Cancer Type), Million, 2021-2032 Figure
109 Italy Molecular Oncology Diagnostics Market
(by Solid Tumor), Million, 2021-2032 Figure 110
Italy Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021-
2032 Figure 111 Spain Molecular Oncology
Diagnostics Market, Million, 2021-2032
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
17
Figure 112 Spain Molecular Oncology Diagnostics
Market (by Cancer Type), Million,
2021-2032 Figure 113 Spain Molecular Oncology
Diagnostics Market (by Solid Tumor), Million,
2021-2032 Figure 114 Spain Molecular Oncology
Diagnostics Market (by Hematological Malignancy),
Million, 2021- 2032 Figure 115 Rest-of-Europe
Molecular Oncology Diagnostics Market, Million,
2021-2032 Figure 116 Rest-of-Europe Molecular
Oncology Diagnostics Market (by Cancer Type),
Million, 2021-2032 Figure 117 Rest-of-Europe
Molecular Oncology Diagnostics Market (by Solid
Tumor), Million, 2021-2032 Figure 118
Rest-of-Europe Molecular Oncology Diagnostics
Market (by Hematological Malignancy), Million,
2021-2032 Figure 119 Asia-Pacific Molecular
Oncology Diagnostics Market (by Region),
Million, 2021-2032 Figure 120 Asia-Pacific
Market Dynamics Figure 121 Asia-Pacific
Molecular Oncology Diagnostics Market (by
Country), Million, 2021 and 2032 Figure 122
China Molecular Oncology Diagnostics Market,
Million, 2021-2032 Figure 123 China Molecular
Oncology Diagnostics Market (by Cancer Type),
Million, 2021-2032 Figure 124 China Molecular
Oncology Diagnostics Market (by Solid Tumor),
Million, 2021-2032 Figure 125 China Molecular
Oncology Diagnostics Market (by Hematological
Malignancy), Million, 2021- 2032 Figure 126
India Molecular Oncology Diagnostics Market,
Million, 2021-2032 Figure 127 India Molecular
Oncology Diagnostics Market (by Cancer Type),
Million, 2021-2032 Figure 128 India Molecular
Oncology Diagnostics Market (by Solid Tumor),
Million, 2021-2032 Figure 129 India Molecular
Oncology Diagnostics Market (by Hematological
Malignancy), Million, 2021- 2032 Figure 130
Japan Molecular Oncology Diagnostics Market,
Million, 2021-2032 Figure 131 Japan Molecular
Oncology Diagnostics Market (by Cancer Type),
Million, 2021-2032 Figure 132 Japan Molecular
Oncology Diagnostics Market (by Solid Tumor),
Million, 2021-2032 Figure 133 Japan Molecular
Oncology Diagnostics Market (by Hematological
Malignancy), Million, 2021- 2032 Figure 134
South Korea Molecular Oncology Diagnostics
Market, Million, 2021-2032 Figure 135 South
Korea Molecular Oncology Diagnostics Market (by
Cancer Type), Million, 2021-2032 Figure 136
South Korea Molecular Oncology Diagnostics Market
(by Solid Tumor), Million, 2021-2032 Figure 137
South Korea Molecular Oncology Diagnostics Market
(by Hematological Malignancy), Million,
2021-2032 Figure 138 Australia Molecular
Oncology Diagnostics Market, Million, 2021-2032
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
18
Figure 139 Australia Molecular Oncology
Diagnostics Market (by Cancer Type), Million,
2021-2032 Figure 140 Australia Molecular
Oncology Diagnostics Market (by Solid Tumor),
Million, 2021-2032 Figure 141 Australia
Molecular Oncology Diagnostics Market (by
Hematological Malignancy), Million, 2021-2032 Fig
ure 142 Rest-of-Asia-Pacific Molecular Oncology
Diagnostics Market, Million, 2021-2032 Figure
143 Rest-of-Asia-Pacific Molecular Oncology
Diagnostics Market (by Cancer Type), Million,
2021- 2032 Figure 144 Rest-of-Asia-Pacific
Molecular Oncology Diagnostics Market (by Solid
Tumor), Million, 2021- 2032 Figure 145
Rest-of-Asia-Pacific Molecular Oncology
Diagnostics Market (by Hematological
Malignancy), Million, 2021-2032 Figure 146
Rest-of-the-World Molecular Oncology Diagnostics
Market, Million, 2021-2032 Figure 147 Total
Number of Companies Profiled Figure 148 Agilent
Technologies, Inc. Product Portfolio Figure 149
Agilent Technologies, Inc. Overall Financials,
Million, 2019-2021 Figure 150 Agilent
Technologies, Inc. Revenue (by Segment),
Million, 2019-2021 Figure 151 Agilent
Technologies, Inc. Revenue (by Region),
Million, 2019-2021 Figure 152 Agilent
Technologies, Inc RD Expenditure, Million,
2019-2021 Figure 153 Abbott. Overall Product
Portfolio Figure 154 Abbott. Overall
Financials, Million, 2019-2021 Figure 155
Abbott. Revenue (by Segment), Million,
2019-2021 Figure 156 Abbott. Revenue (by
Region), Million, 2019-2021 Figure 157
Abbott. RD Expenditure, Million, 2019-2021
Figure 158 Biocartis NV. Product
Portfolio Figure 159 Biocartis NV Overall
Financials, Million, 2019-2021 Figure 160
Bio-Rad Laboratories, Inc. Product
Portfolio Figure 161 Bio-Rad Laboratories, Inc.
Overall Financials, Million, 2019-2021 Figure
162 Bio-Rad Laboratories, Inc. Revenue (by
Segment), Million, 2019-2021 Figure 163
Bio-Rad Laboratories, Inc. Revenue (by Region),
Million, 2019-2021 Figure 164 Bio-Rad
Laboratories, Inc. RD Expenditure, Million,
2019-2021 Figure 165 F. Hoffmann-La Roche Ltd.
Product Portfolio Figure 166 F. Hoffmann-La
Roche Ltd. Overall Financials, Million,
2019-2021 Figure 167 F. Hoffmann-La Roche Ltd.
Revenue (by Segment), Million, 2019-2021 18
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
19
Figure 168 F. Hoffmann-La Roche Ltd. Revenue
(by Region), Million, 2019-2021 Figure 169 F.
Hoffmann-La Roche Ltd. RD Expenditure,
Million, 2019-2021 Figure 170 QIAGEN N.V.
Product Portfolio Figure 171 QIAGEN N.V.
Overall Financials, Million, 2019-2021 Figure
172 QIAGEN N.V. Revenue (by Segment), Million,
2019-2021 Figure 173 QIAGEN N.V. Revenue (by
Region), Million, 2019-2021 Figure 174 QIAGEN
N.V. RD Expenditure, Million, 2019-2021
Figure 175 Thermo Fisher Scientific, Inc.
Product Portfolio Figure 176 Thermo Fisher
Scientific, Inc. Overall Financials, Million,
2019-2021 Figure 177 Thermo Fisher Scientific,
Inc. Revenue (by Segment), Million, 2019-2021
Figure 178 Thermo Fisher Scientific, Inc.
Revenue (by Region), Million, 2019-2021 Figure
179 Thermo Fisher Scientific, Inc. RD
Expenditure, Million, 2019-2021 Figure 180
Danaher. Product Portfolio Figure 181 Danaher.
Overall Financials, Million, 2019-2021 Figure
182 Danaher. Revenue (by Segment), Million,
2019-2021 Figure 183 Danaher. Revenue (by
Region), Million, 2019-2021 Figure 184
Danaher. RD Expenditure, Million, 2019-2021
Figure 185 Guardant Health Overall Product
Portfolio Figure 186 Guardant Health Overall
Financials, Million, 2019-2021 Figure 187
Guardant Health Revenue (by Segment), 2019-2021
Figure 188 Guardant Health RD Expenditure,
Million, 2019-2021 Figure 189 HTG Molecular
Diagnostics, Inc. Overall Product
Portfolio Figure 190 HTG Molecular Diagnostics,
Inc. Overall Financials, Million, 2019-2021
Figure 191 HTG Molecular Diagnostics, Inc.
Revenue (by Segment), 2019-2021 Figure 192 HTG
Molecular Diagnostics, Inc. RD Expenditure,
Million, 2019-2021 Figure 193 Illumina, Inc.
Overall Product Portfolio Figure 194 Illumina,
Inc. Overall Financials, Million, 2019-2021
Figure 195 Illumina, Inc. Revenue (by Segment),
Million, 2019-2021 Figure 196 Illumina, Inc.
Revenue (by Region), Million, 2019-2021 Figure
197 Illumina, Inc. RD Expenditure, Million,
2019-2021 Figure 198 Invivoscribe, Inc.
Overall Product Portfolio Figure 199 Myriad
Genetics, Inc. Product Portfolio Figure 200
Myriad Genetics, Inc. Overall Financials,
Million, 2019-2021
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
20
Figure 201 Myriad Genetics, Inc. Revenue (by
Segment), Million, 2019-2021 Figure 202 Myriad
Genetics, Inc. RD Expenditure, Million,
2019-2021 Figure 203 Sysmex Corporation
Overall Product Portfolio Figure 204 Sysmex
Corporation Overall Financials, Million,
2019-2021 Figure 205 Sysmex Corporation
Revenue (by Region), Million, 2019-2021 Figure
206 Sysmex Corporation RD Expenditure,
Million, 2019-2021
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
21
List of Tables
Table 1
Biomarkers for Different Cancer Types
Table 2
Cost of Liquid Biopsy Based NGS Diagnostic Kits
Table 3
Companies Providing Kits and Assays for Molecular
Oncology Diagnostics
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
22
BIS Research Offerings
We are on a mission to harness the potential of
disruptive technologies to make businesses thrive
in todays digital age. We have a vision to be a
leading and a preferred knowledge partner for
corporates and institutions worldwide and assist
them with market intelligence in the area of
emerging technologies, advisories, and other
innovative solutions.
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
Know More
Know More
Know More
Know More
23
Disclaimer
BIS Research Inc. provides valuable market
intelligence to an exclusive group of customers
in response to orders. The report is licensed
for the customer's internal use only and is
subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium
or in any form for any purpose, without the
express written consent of BIS Research Inc.
Customer will not disclose the contents of the
report, whether directly in any media or
indirectly through incorporation in a database,
marketing list, report or otherwise, or use or
permit the use of Information to generate any
statistical or other information that is or will
be provided to third parties or voluntarily
produce Information in legal proceedings.
Market reports are based on expectations,
estimates and projections as of the date such
information is available. Any recommendation
contained in this report may not be suitable for
all investors or businesses. The market
conclusions drawn are necessarily based upon a
number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of
the date of such statements, are inherently
subject to market fluctuations and business,
economic and competitive uncertainties and
contingencies.
For more details regarding permission, please
contact us Email sales_at_bisresearch.com Tel 1
510 404 8135
GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET
24
T E K R A M C I T S O N G A I D Y G O
L O C N O R A L U C E L O M L A B O
L 24 G All rights reserved at BIS Research Inc.
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
hello_at_bisresearch.com Call Us 1-510-404-8135
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel [phone]
www.bisresearch.com